The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
The Food and Drug Administration has authorized the use of Zepbound for adults with obesity and moderate to severe obstructive sleep apnea.
The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea.the use of Zepbound, made by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea , a common condition where a person struggles to breathe properly during sleep. The federal agency advises that the drug is used in combination with a reduced-calorie diet and increased exercise.
Sleep apnea occurs when a person's upper airway becomes blocked. While it can affect anyone, it is more prevalent among those who are overweight.In two studies with adults who had obesity and moderate to severe OSA over a 52-week period, participants who received Zepbound experienced a"statistically significant and clinically meaningful reduction" in episodes of shallow breathing or temporary pauses in breathing while asleep compared to those who received a placebo, the FDA said.
Although this class of drugs, called GLP-1 agonists, was developed two decades ago, research into their potential uses is still in the early stages.Wegovy to be used to reduce the risk of strokes, heart attacks, and other cardiovascular problems in patients who are overweight.Juliana Kim is a weekend reporter for Digital News, where she adds context to the news of the day and brings her enterprise skills to NPR's signature journalism.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Read more »
FDA approves weight loss drug Zepbound for sleep apneaBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA Approves Weight-Loss Drug Zepbound for Sleep ApneaIt’s the first prescription drug to be approved to treat the condition.
Read more »
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaThe FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Read more »
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortageThe decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
Read more »
FDA approves Eli Lilly’s obesity medication for obstructive sleep apneaIn a study, people who took Zepbound had fewer breathing interruptions.
Read more »